Clinical trial · Interventional
Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease
Feasibility of Granulocyte-Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow From Pediatric Donors as a Stem Cell Source for Allogeneic Bone Marrow Transplant
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: A bone marrow transplant from a brother or sister may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. Colony-stimulating factors, such as G-CSF, cause the body to make blood cells. Giving G-CSF to the donor may help the body make more stem cells that can be collected for bone marrow transplant and may cause fewer side effects in the patient after the transplant. PURPOSE: This phase I/II trial is studying the side effects of donor bone marrow transplant and to see how well it works in treating young patients with cancer or a non-cancerous disease.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic bone marrow transplantation | Procedure | — | UNRESOLVED |
| filgrastim | Biological | Filgrastim | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Safety and feasibility
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Patients (recipients):
* Undergoing a myeloablative or nonmyeloablative allogeneic bone marrow transplantation for 1 of the following diseases:
* Hematologic malignancy
* Non-hematologic malignancy
* Non-malignant disease
* Not undergoing T-cell depleted bone marrow transplantation
* Donors:
* Healthy sibling of a patient meeting eligibility requirements for this protocol
* HLA-identically matched with patient
PATIENT CHARACTERISTICS:
Age
* 18 and under (patient and donor)
Performance status
* Karnofsky 90-100% (donor) OR
* Lansky 90-100% (donor)
Life expectancy
* Not specified
Hematopoietic
* No sickle cell anemia (donor)
Hepatic
* Not specified
Renal
* Not specified
Immunologic
* HIV negative (patient and donor)
* No uncontrolled bacterial, viral, fungal, or parasitic infection (donor)
* No potentially life threatening autoimmune disease (donor)
Other
* Not pregnant or nursing (patient and donor)
* Fertile patients must use effective contraception (patient)
* No other illness that would severely limit life expectancy (patient)
* No pre-existing medical condition that would confer a high risk for bone marrow donation (donor)
* No medical condition or psychiatric trait that would preclude G-CSF administration or bone marrow harvesting (donor)
PRIOR CONCURRENT THERAPY:
Biologic therapy
* More than 4 years since prior allogeneic blood transfusion (donor)
* No concurrent growth factors post-transplantation (donor)
Chemotherapy
* Not specified
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specified
Other
* Concurrent participation in another treatment clinical trial allowed provided the use of filgrastim (G-CSF)-mobilized bone marrow is not excluded (patient)
* No other concurrent investigational agents (donor)References
Publications (0)
Data not yet available